Evidence map›Paper›PMID 34351813›Full record

ArticleJCO global oncology2021

Emerging Use of Public-Private Partnerships in Public Radiotherapy Facilities in Nigeria.

Chidinma P Anakwenze Akinfenwa, Abiola Ibraheem, Kenneth Nwankwo, Nwamaka Lasebikan, Musa Ali-Gombe, Usman Malami Aliyu, Emmanuel Ikhile, Omobolanle Adegboyega, Adamu Abdullahi, Ann H Klopp and 7 more

Abstract read
In one paragraph

Article in JCO global oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Chidinma P Anakwenze AkinfenwaDivision of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-1324-4410
Abiola IbraheemSection of Hematology Oncology, University of Chicago, Chicago, IL.ORCID 0000-0002-6593-7908
Kenneth NwankwoDepartment of Radiation Medicine, College of Medicine, University of Nigeria, Nsukka, Nigeria.
Nwamaka LasebikanDepartment of Radiation Medicine, University of Nigeria Teaching Hospital, Enugu, Nigeria.ORCID 0000-0002-3775-0492
Musa Ali-GombeRadiology Department, Gombe State University, Gombe, Gombe State, Nigeria.ORCID 0000-0002-4431-7777
Usman Malami AliyuDepartment of Radiotherapy and Oncology, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Sokoto State, Nigeria.
Emmanuel IkhileDepartment of Radiation Oncology, University of Benin Teaching Hospital, Benin, Edo State, Nigeria.
Omobolanle AdegboyegaLagos University Teaching Hospital, Lagos, Lagos State, Nigeria.ORCID 0000-0001-5208-8073
Adamu AbdullahiDepartment of Radiotherapy and Oncology, Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State, Nigeria.ORCID 0000-0002-2223-3820
Ann H KloppDivision of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Kathleen SchmelerGynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-9670-4189
Lilie L LinDivision of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-7681-8966
Anuja JhingranDivision of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-0697-1815
Brandi R PageDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Jim LengThe University of Chicago Pritzker School of Medicine, Chicago, IL.ORCID 0000-0001-8482-4776
Surbhi GroverDepartment of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; Botswana-UPENN Partnership, Gaborone, Botswana.ORCID 0000-0001-7443-5937
Atara NtekimDepartment of Radiation Oncology, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria.ORCID 0000-0003-4830-8365

Funding

Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrenceK08CA230170 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GROVER, SURBHI · 2019 to 2023
$1.4M
NCI NIH HHS K08 CA230170
6 · The paper itself

Abstract

purposeRadiotherapy (RT) treatment at public hospitals in Nigeria is often interrupted by prolonged periods of machine breakdown because of insufficient funds for maintenance and repair. These delays have prompted the uptake of public-private partnerships (PPPs) to acquire and maintain RT equipment. This study aimed to understand Nigeria's current RT capacity and the impact of PPPs on RT availability and cost.

methodsEleven radiation oncologists, each representing one of the 11 RT centers in Nigeria (eight public and three private), were invited to complete a survey on the type, status, acquisition, and maintenance plan of existing RT equipment, cost incurred by patients for external-beam radiation (EBRT) and brachytherapy treatment, and number of patients treated per year on each machine. Type and status of equipment at nonresponding facilities were obtained through literature review and confirmed with the facility.

resultsA total of eight (81%) respondents completed the survey, all representing public centers, three of which reported PPP use. They reported 11 megavoltage units in total (seven linear accelerators [LINACs] and four Cobalt-60s) and 10 brachytherapy afterloaders. Of those, 57% (4/7) of the LINACs, 100% (4/4) of the Cobalt-60s, and 63% (7/11) of the afterloaders were in clinical use. All commissioned equipment supported by PPPs (three LINACs and one afterloader) were in operation. The public EBRT equipment were nonfunctional 35% of the year (resulting in 60% fewer patients treated per year). The PPP EBRT and afterloaders did not experience any periods of breakdown, but PPP costs were 338% higher than public equipment.

conclusionThis study characterizes the use of PPP as a more reliable method of RT delivery in Nigeria, albeit at higher costs.

Indexed as

BrachytherapyRadiation OncologyHumansNigeriaParticle AcceleratorsPublic-Private Sector Partnerships

Identifiers

PMID34351813
PMCPMC8389883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.